Drug class
Oral SARS-CoV-2 3-chymotrypsin-like protease (3CLpro/Mpro) inhibitor; antiviral
Mechanism of action
Inhibits the SARS-CoV-2 main protease (3CLpro/Mpro), preventing cleavage of viral polyproteins required for replication and assembly of functional viral proteins.
General use cases
- Post-exposure prophylaxis of COVID-19 in adults and adolescents aged 12 years and older under the EU-authorised ZOKOVEA indication (EU marketing authorisation issued 18 September 2026). Do not extrapolate this indication to treatment of established COVID-19 or other jurisdictions without a corresponding authorisation.
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
